Status:
COMPLETED
An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia
Lead Sponsor:
Cumberland Pharmaceuticals
Conditions:
Hyponatremia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will investigate the application of a vasopressin antagonist in the treatment of hyponatremia most likely caused by inappropriate AVP secretion. The population studied will include patients...
Eligibility Criteria
Inclusion
- Serum sodium levels less than or equal 130mEq/L
- Euvolemic or Hypervolemic hyponatremia
Exclusion
- Clinical evidence of volume depletion or dehydration
- Untreated severe hypothyroidism, hyperthyroidism, or adrenal insufficiency
- Uncontrolled brady-or tachyarrhythmias requiring pacemaker placement or treatment
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2005
Estimated Enrollment :
251 Patients enrolled
Trial Details
Trial ID
NCT00379847
Start Date
February 1 2004
End Date
June 1 2005
Last Update
May 2 2014
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
Tuscon, Arizona, United States, 85723
2
Denver, Colorado, United States, 80262
3
Washington D.C., District of Columbia, United States, 20007
4
Augusta, Georgia, United States, 30901